Some companies with expected catalysts


Johnson & Johnson Merck & Co. Neuralstem Inc.

Sagient Research

A Streetwise Reports Partner

Top Investors and Analysts Use This Exclusive Report to Anticipate the Prospects of Medical and Biotech Stocks.

Now you can, too!

Access to The BioMed Tracker Report usually costs $2,000. For a limited time you can get access to the Report for FREE.


Biomedical stocks can soar depending on key catalysts and outcomes, such as FDA approval, regulatory changes, and clinical studies. The more accurately you can anticipate the results, the higher your profits.

We know that portfolio managers and analysts will pay big bucks for top-flight investment research. And for many investors and analysts the ultimate interactive biotech & pharmaceutical investment tool is the BioMedTracker Report -–, from Sagient Research:

  • The BioMedTracker Outlook report is sorted by catalyst type, date and company, giving you quick, sortable access to exclusive information.
  • The Report is part of a membership which usually costs $2,000 per year.

Right now, for a limited time, Sagient is offering free access to the current BioMedTracker Report to readers of Streetwise Reports.

— 2013 Early Outlook Report —
Sorted by Type of Catalyst | Sorted by Date | Sorted by Company